EXON-SKIPPING FOR DUCHENNE
Eteplirsen, our lead clinical candidate, is designed to skip exon 51. A candidate for exon 53 skipping (SRP-4053) is in clinical development, and a candidate for exon 45 skipping (SRP-4045) has entered early clinical development. We also have other drug candidates in discovery and preclinical development that are designed to skip exons 44, 52, 50, 43, 55, 8 and 35, and we are committed to exploring the potential of our technology to address all DMD patients who may be candidates for exon skipping.
